Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

David J. Gibson, Mark G. Ward, Clarissa Rentsch, Antony B. Friedman, Kirstin M. Taylor, Miles P. Sparrow, Peter R. Gibson

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Background: Clinical application of therapeutic drug monitoring (TDM) to optimise anti-TNF therapies in patients with IBD depends upon target ranges. Aims: To review methodology used to determine therapeutic ranges and critically compare and contrast its application to infliximab and adalimumab. Methods: A systematic review was performed, and relevant literature was summarised and critically examined. Results: Upper limits of the therapeutic range are determined by toxicity, a plateau response and cost. Lower limits are determined by optimal concentration on the target of action in vitro and/or in vivo, or by correlation of drug levels with clinical efficacy using area-under-receiver-operator-curve (AUROC) analysis. In 43 studies, there were huge variations in time at which infliximab and adalimumab levels were measured, the end-points used (clinical remission to mucosal healing), the clinical setting (active disease vs maintenance phase) and the reason for TDM (proactive vs reactive). In the maintenance phase for infliximab, lower trough limits 2.8-5.7 µg/mL are reported depending upon end-points used, with consistent AUROC 0.68-0.77. Adalimumab TDM targets are even less consistent with a lower limit 5.9-11.8 µg/mL (AUROC 0.66-0.83) in some studies, but no cut-off can be identified that is significantly associated with outcome in others, related to inherent pharmacokinetic and pharmacodynamic differences, and heterogeneity of study design. Conclusions: Evidence for exposure-response relationship is stronger for infliximab than adalimumab. Due to heterogeneity in settings for drug level measurements, therapeutic ranges vary. These factors need to be taken into account when interpreting the evidence and extending this to therapeutic strategies for IBD patients.

Original languageEnglish
Pages (from-to)612-628
Number of pages17
JournalAlimentary Pharmacology & Therapeutics
Volume51
Issue number6
DOIs
Publication statusPublished - Mar 2020

Cite this